Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  7,672 results for ""TYPE 2 diabetes""

Your Filters

Publication : lancet
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Subjects: NOVO Nordisk A/S; TYPE 2 diabetes; SEMAGLUTIDE

  • Source: Lancet. 8/26/2023, Vol. 402 Issue 10403, p720-730. 11p.

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.

Subjects: NOVO Nordisk A/S; TYPE 2 diabetes; SEMAGLUTIDE

  • Source: Lancet. 8/26/2023, Vol. 402 Issue 10403, p693-704. 12p.

Record details

Read More Add to Saved list
×
Academic Journal

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Subjects: ELI Lilly & Co.; TYPE 2 diabetes; CLINICAL trials

  • Source: Lancet. Aug2023, Vol. 402 Issue 10402, p613-626. 14p.

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.

Subjects: TYPE 2 diabetes; ELI Lilly & Co.; WATER restrictionsSLOVAKIA; POLAND; HUNGARY

  • Source: Lancet. 8/5/2023, Vol. 402 Issue 10400, p472-483. 12p.

Record details

Read More Add to Saved list
×
Academic Journal

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.

Subjects: TYPE 2 diabetes; INSULIN aspart; INSULIN

  • Source: Lancet. Jun2023, Vol. 401 Issue 10392, p1929-1940. 12p.

Record details

Read More Add to Saved list
×
Academic Journal

CagriSema and the link between obesity and type 2 diabetes.

Subjects: TYPE 2 diabetes; OBESITY

  • Source: Lancet. 8/26/2023, Vol. 402 Issue 10403, p671-673. 3p.

Record details

Read More Add to Saved list
×
Academic Journal

The pursuit of optimal semaglutide dosing in type 2 diabetes continues.

Subjects: TYPE 2 diabetes; SEMAGLUTIDE

  • Source: Lancet. 8/26/2023, Vol. 402 Issue 10403, p668-669. 2p.

Record details

Read More Add to Saved list
×
Academic Journal

SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide.

Subjects: TYPE 2 diabetes; OBESITY

  • Source: Lancet. Aug2023, Vol. 402 Issue 10402, p586-588. 3p.

Record details

Read More Add to Saved list
×
Academic Journal

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.

Subjects: TYPE 2 diabetes; ARENAS

  • Source: Lancet. Aug2023, Vol. 402 Issue 10401, p504-505. 2p.

Record details

Read More Add to Saved list
×
Academic Journal

Type 2 diabetes.

Subjects: TYPE 2 diabetes; GLYCEMIC control; YOUNG adults

  • Source: Lancet. Nov2022, Vol. 400 Issue 10365, p1803-1820. 18p.

Record details

Read More Add to Saved list
×
  • 1-10 of  7,672 results for ""TYPE 2 diabetes""